4basebio (LSE:4BB) Beneish M-Score: -2.00 (As of Jun. 25, 2026)


LSE:4BB 4basebio PLC LSE:4BB
61 GF Score
Price £5.25
GF Value £28.17
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is 4basebio Beneish M-Score?

4basebio LSE:4BB 61 Beneish M-Score is -2.00 as of Jun. 25, 2026. GuruFocus rates LSE:4BB with a GF Score™ of 61/100 and a GF Value™ of £28.17 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 831 Biotechnology companies, 4basebio ranks worse than 61.49% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for 4basebio's Beneish M-Score or its related term are showing as below:

LSE:4BB' s Beneish M-Score Range Over the Past 10 Years
Min: -2.59   Med: -2.45   Max: -1.56
Current: -2

During the past 7 years, the highest Beneish M-Score of 4basebio was -1.56. The lowest was -2.59. And the median was -2.45.

4basebio Beneish M-Score Historical Data

* Premium members only.

The historical data trend for 4basebio's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4basebio Beneish M-Score Chart

4basebio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -2.59 -2.57 -2.45 -1.56 -2.00

4basebio Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.45 0.00 -1.56 0.00 -2.00

LSE:4BB vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, 4basebio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

4basebio Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 4basebio's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where 4basebio's Beneish M-Score falls into.


LSE:4BB
61GF Score
4basebio PLC LSE:4BB
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

4basebio Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of 4basebio for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5628+0.528 * 1.1737+0.404 * 2.0932+0.892 * 1.8146+0.115 * 0.8014
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7032+4.679 * -0.04457-0.327 * 1.6037
=-2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was £0.29 Mil.
Revenue was £1.69 Mil.
Gross Profit was £0.97 Mil.
Total Current Assets was £20.66 Mil.
Total Assets was £29.55 Mil.
Property, Plant and Equipment(Net PPE) was £4.03 Mil.
Depreciation, Depletion and Amortization(DDA) was £1.15 Mil.
Selling, General, & Admin. Expense(SGA) was £2.25 Mil.
Total Current Liabilities was £2.83 Mil.
Long-Term Debt & Capital Lease Obligation was £16.55 Mil.
Net Income was £-16.91 Mil.
Gross Profit was £0.00 Mil.
Cash Flow from Operations was £-15.59 Mil.
 Total Receivables was £0.28 Mil.
Revenue was £0.93 Mil.
Gross Profit was £0.63 Mil.
Total Current Assets was £36.89 Mil.
Total Assets was £44.73 Mil.
Property, Plant and Equipment(Net PPE) was £4.33 Mil.
Depreciation, Depletion and Amortization(DDA) was £0.93 Mil.
Selling, General, & Admin. Expense(SGA) was £1.77 Mil.
Total Current Liabilities was £3.27 Mil.
Long-Term Debt & Capital Lease Obligation was £15.03 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.289 / 1.693) / (0.283 / 0.933)
=0.170703 / 0.303323
=0.5628

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.63 / 0.933) / (0.974 / 1.693)
=0.675241 / 0.57531
=1.1737

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (20.664 + 4.027) / 29.549) / (1 - (36.888 + 4.326) / 44.727)
=0.164405 / 0.078543
=2.0932

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.693 / 0.933
=1.8146

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.933 / (0.933 + 4.326)) / (1.145 / (1.145 + 4.027))
=0.17741 / 0.221384
=0.8014

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2.252 / 1.693) / (1.765 / 0.933)
=1.330183 / 1.891747
=0.7032

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((16.553 + 2.828) / 29.549) / ((15.028 + 3.265) / 44.727)
=0.655894 / 0.408992
=1.6037

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-16.905 - 0 - -15.588) / 29.549
=-0.04457

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

4basebio has a M-score of -2.00 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.00 mean?
4basebio (LSE:4BB) has a Beneish M-Score of -2.00 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on 4basebio and its competitors. According to the industry distribution chart, 4basebio ranks #511 out of 831 companies in the Biotechnology industry, placing it in the top 61.5%.
Is 4basebio's Beneish M-Score too high?
4basebio's current Beneish M-Score is -2.00. Based on the distribution chart, 4basebio ranks #511 out of 831 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 4basebio has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4basebio's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 4basebio ranks #511 out of 831 companies for Beneish M-Score. This places 4basebio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on 4basebio and its competitors. 4basebio's current Beneish M-Score is -2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4basebio stock overvalued right now?
Based on GuruFocus' analysis, 4basebio (LSE:4BB) is currently considered Possible Value Trap. The stock's GF Value™ is £28.17, compared to a current price of £5.25 — trading 81.4% below its estimated fair value. The current Beneish M-Score is -2.00. 4basebio's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For 4basebio (LSE:4BB), the current Beneish M-Score is -2.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4basebio (LSE:4BB) Overvalued in 2026?

Based on GuruFocus' analysis, 4basebio stock appears to be undervalued. The current stock price of £5.25 is trading 81.4% below its estimated GF Value™ of £28.17. GuruFocus considers 4basebio to be Possible Value Trap.

Key valuation signals for LSE:4BB:

  • Beneish M-Score: -2.00
  • GF Value™: £28.17 vs. price of £5.25 (81.4% below fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the LSE:4BB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4basebio Business Description

Other Exchanges 88Q:Germany
Address 25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
61GF Score

Get the complete analysis for LSE:4BB

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£5.25
Price
£28.17
GF Value